The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for S Koni Reddy
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Promoter and Director S Koni Reddy, along with two other promoters (S. Nagi Reddy and S. Manoj Kumar Reddy), disclosed acquisition of shares and warrants in Concord Drugs Ltd through a preferential allotment on 20 November 2025. Together the three promoters picked up 5,00,000 equity shares (2,00,000 + 1,50,000 + 1,50,000) and 18,00,000 warrants (7,00,000 + 5,50,000 + 5,50,000). Combined promoter holding moved from 54.39% to 50.92% of the expanded equity capital (rising to 58.74% on a fully diluted basis once warrants convert). The company's equity base grew from 1.00 crore to about 1.32 crore shares, indicating fresh capital infusion from promoters.
Net positive for shareholders — promoters are putting additional skin in the game, which usually signals confidence in the company's prospects. However, the preferential allotment dilutes existing retail shareholders, so investors should watch for the stated purpose of the capital raise and the warrant conversion terms.